vcp

CB-5083 是一种有效的、选择性的、可口服的 p97 AAA ATPase 抑制剂，IC50为 11 nM。

NPD8733 是癌细胞增强的成纤维细胞迁移抑制剂。它是与多种细胞活动 (AAA+) 蛋白家族相关的 ATP 酶的成员，能够与含 valosin 的蛋白 (VCP) p97特异性结合，对癌症疾病具有潜在的研究价值。

NMS873 是一种有效的选择性变构 VCP p97 抑制剂，IC50值为 30 nM。

DBEQ (JRF 12) 是一种选择性的，ATP 竞争性p97抑制剂，对 p97(wt) 和 p97(C522A) 的IC50值分别为 1.5 μM 和 1.6 μM，也可抑制Vps4，IC50值为 11.5 μM。

ML241 hydrochloride 是一种有效且选择性的 p97 ATPase 抑制剂，IC50值为 100 nM。

Mal-PEG2-VCP-Eribulin is a chemotherapeutic compound comprising an antibody-drug conjugate (ADC) linker (Mal-PEG2-VCP) and the microtubule inhibitor Eribulin[1]. This compound uniquely targets microtubules, offering a novel approach to cancer treatment. Eribulin is specifically utilized in creating targeted Eribulin-based drugs for antibody conjugates[1].

Mal-PEG2-VCP-NB is a noncleavable ADC linker comprising a Maleimide group, a 2-unit PEG, and a VCP NB.

VCP-Eribulin, an Eribulin-based drug for antibody conjugates[1], combines the VCP (ADCs linker) with Eribulin, a distinct microtubule inhibitor used in cancer treatments[2].

VCP p97 inhibitor-1, a highly effective compound, inhibits VCP p97 (also known as Cdc48, CDC-48, or Ter94) with an IC 50 of 54.7 nM. This inhibitor induces a disruption in protein homeostasis and interferes with the degradation process of misfolded polypeptides by the ubiquitin-proteasome system (UPS).

VCP-746 is a potent adenosine A2B receptor agonist that stimulates anti-fibrotic signalling. VCP746 reduces hypertrophy in a rat neonatal cardiac myocyte model. VCP746 is a hybrid molecule consisting of an adenosine moiety linked to an adenosine A1 receptor (A1AR) allosteric modulator moiety. At the A1AR, VCP746 mediated cardioprotection in the absence of haemodynamic side effects such as bradycardia.

Compound 17 (Mal-PEG4-VCP-NB) 是一种含有 Maleimide 基团、4 单元 PEG 及 VCP NB 的可降解ADC linker。

Mal-PEG3-VCP-NB (Compound 25c) 作为一种ADC linker，具备 Maleimide 基团、三个 PEG 单元及 VCP NB，是可降解性的。

ML240 是一种选择性的 ATP 竞争性 p97 抑制剂，IC50值为 100 nM。

NMS-859 是一种有效的含 valosin 蛋白 (VCP) p97 的共价抑制剂，在细胞中存在 60 μM 和 1 mM ATP 的情况下，对野生型 VCP 的 IC50 分别为 0.37 μM 和 0.36 μM。

aPKC-I is an inhibitor of atypical protein kinase C (aPKC ) which inhibits both PKCζ and PKCι with high specificity and prevents VEGF-induced endothelial permeability in cell culture and in vivo, thereby blocking ischemia-reperfusion (IR)-induced permeability.

VPC171 是一种新型腺苷 A1 受体正变构调节剂 (PAM)。

Doxorubicin-MVCP (MC-Val-Cit-PAB-Doxorubicin) is a Doxorubicin derivative with an MC-Val-Cit-PAB linker.

Paclitaxel-MVCP ( MC-val-cit-pab-paclitaxel )is a paclitaxel derivative with an MC-Val-Cit-PAB linker, which can be used for the preparation of Paclitaxel conjugates for drug delivery and nanomedicine research.

VCPIP1-IN-1 是一种 VCPIP1 抑制剂，可用于研究癌症。

BCN-HS-PEG2(vcPABC-MMAE)2 作为一种用于ADC合成的连接子。

VCPIP1-IN-1（化合物076）作为VCPIP1抑制剂，具有特定的生物活性。

BCN-PEG3-VC-PFP ester is a three-unit PEG ADC linker that can be cleaved, and it is commonly employed in the synthesis of antibody-drug conjugates (ADCs) [1].

Boc-NH-PEG3-C2-triazole-DBCO-PEG4-VC-PAB-DMEA is a double-cleavable PEG linker (3-unit and 4-unit) designed for antibody-drug conjugation (ADC).

DBCO-(PEG2-VC-PAB-MMAE)2 consists of Monomethyl auristatin E (MMAE), a toxin payload in antibody-drug conjugate [1], conjugated to the cleavable linker DBCO-(PEG2-VC-PAB)2. MMAE, a potent tubulin inhibitor, serves as the cytotoxic component in this formulation.